O'Connor Wendi, Quintana Megan, Smith Scott, Willis Monte, Renner Jordan
Department of Radiology, University of North Carolina Hospitals, Chapel Hill, NC, USA ; Department of Pathology & Laboratory Medicine, University of North Carolina Hospitals, Chapel Hill, NC, USA.
Department of Surgery, University of North Carolina Hospitals, Chapel Hill, NC, USA.
J Radiol Case Rep. 2014 Jun 30;8(6):27-38. doi: 10.3941/jrcr.v8i6.1328. eCollection 2014 Jun.
An 87 year-old white female presented with a two-year history of intermittent discomfort in her left foot. PET-CT identified intense18F-fluorodeoxyglucose (FDG) uptake corresponding to the lesion. Histology of a fine needle aspiration and open biopsy were consistent with a benign giant cell tumor (GCT) of the bone. GCT of bone is an uncommon primary tumor typically presenting as a benign solitary lesion that arises in the end of the long bones. While GCT can occur throughout the axial and appendicular skeleton, it is exceedingly uncommon in the bone of the foot. While 18F-FDG has been established in detecting several malignant bone tumors, benign disease processes may also be identified. The degree of 18F-FDG activity in a benign GCT may be of an intensity that can be mistakenly interpreted as a malignant lesion. Therefore, GCT of the bone can be included in the differential diagnosis of an intensely 18F-FDG-avid neoplasm located within the tarsal bones.
一位87岁的白人女性，有两年间歇性左脚不适病史。PET-CT显示与病变部位相对应的18F-氟脱氧葡萄糖（FDG）摄取增强。细针穿刺活检和切开活检的组织学结果与骨良性巨细胞瘤（GCT）相符。骨GCT是一种不常见的原发性肿瘤，通常表现为良性孤立性病变，发生于长骨末端。虽然GCT可发生于整个中轴骨和四肢骨骼，但在足部骨骼中极为罕见。虽然18F-FDG已被用于检测多种恶性骨肿瘤，但也可能识别出良性疾病过程。良性GCT中18F-FDG的活性程度可能会被错误地解释为恶性病变。因此，骨GCT可列入跗骨内18F-FDG摄取强烈的肿瘤的鉴别诊断范围。
